New hope for chagas: experimental drug aims to wipe out parasites

NCT ID NCT06632600

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called LXE408 in 130 adults with chronic Chagas disease who do not have severe organ damage. The goal is to see if LXE408 can clear or reduce the parasite level in the blood over 6 months, compared to placebo and standard treatment. Participants take the drug by mouth for 28 days, and researchers check for parasites using a sensitive test (PCR) at several time points.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

LXE408 (an experimental oral drug)

What this could lead to

If successful, this could provide a new treatment option for chronic Chagas disease, potentially reducing parasite levels and preventing disease progression.

What could go wrong

This is an early Phase 2 trial with only 130 participants, so results may not apply to everyone. The drug may not clear parasites as hoped, and side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHAGAS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chagas disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030-3411, United States

    Contact

    Contact Email: •••••@•••••

  • Boston Medical Center

    RECRUITING

    Boston, Massachusetts, 02118, United States

    Contact

    Contact Email: •••••@•••••

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, 1407, Argentina

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, C1221ADC, Argentina

  • Novartis Investigative Site

    RECRUITING

    Caba, C1015ABO, Argentina

  • Novartis Investigative Site

    RECRUITING

    Corrientes, W3400CDS, Argentina

  • Novartis Investigative Site

    RECRUITING

    Córdoba, X5016KEH, Argentina

  • Novartis Investigative Site

    RECRUITING

    Formosa, P3600KGC, Argentina

  • Novartis Investigative Site

    RECRUITING

    Montes Claros, Minas Gerais, 39401-001, Brazil

  • Novartis Investigative Site

    RECRUITING

    Recife, Pernambuco, 50100-060, Brazil

  • Novartis Investigative Site

    RECRUITING

    Rio de Janeiro, Rio de Janeiro, 21040-360, Brazil

  • Novartis Investigative Site

    RECRUITING

    São Caetano do Sul, São Paulo, 09521-160, Brazil

  • Novartis Investigative Site

    RECRUITING

    Barranquilla, Atlántico, 080005, Colombia

  • Novartis Investigative Site

    RECRUITING

    Yopal, Casanare Department, 850009, Colombia

  • Novartis Investigative Site

    RECRUITING

    Bogotá, 110131, Colombia

  • Novartis Investigative Site

    RECRUITING

    Bogotá, 111411, Colombia

  • Novartis Investigative Site

    RECRUITING

    Floridablanca, 681017, Colombia

  • Novartis Investigative Site

    RECRUITING

    San Gil, 684031, Colombia

  • Olive View UCLA Educ and Res Ins

    RECRUITING

    Sylmar, California, 91342, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Florida Shands

    RECRUITING

    Gainesville, Florida, 32610-0486, United States

    Contact Email: •••••@•••••

    Contact